Critical Appraisal in Breast Cancer: The Essentials in 30 Minutes.

Here is a live recording of a talk I gave at SAMO on 27 February 2026.

Feb 28 • Timothée Olivier

9

1

33:54

The PATINA trial – palbociclib maintenance in metastatic breast cancer.

What is the best 1st-line strategy in patients with HR+/HER2+ advanced/metastatic breast cancer?

Feb 8 • Timothée Olivier

15

4

January 2026

The puzzle of PARP inhibitors plus ARPI in Prostate Cancer: 12 mutations, 3 trials, and 5 different labels.

In a new paper just published in eClinicalMedicine, part of the Lancet group, we discuss, together with Sahar van Waalwijk, the fascinating consequences…

Jan 22 • Hans Westgeest and Timothée Olivier

17

2

December 2025

Aging Out of Evidence: Why Cancer Trials Still Miss Older Adults

There is a need for trials mirroring real-world practices.

Dec 24, 2025 • Alyson Haslam

19

1

How To Study Drugs With Apparent Massive Effect Sizes, Still Using Randomization?

We proposed a trial design to answer this question.

Dec 16, 2025 • Timothée Olivier

18

3

2

Placebo First, Treatment Later: Is This Fair to Patients With Active Cancer?

In a new paper, we examined the randomized trials using inert control arms (mostly placebo only) leading to FDA approvals.

Dec 14, 2025 • Timothée Olivier

19

4

An Interview with Professor Rajshekhar Chakraborty: How Should We Care for Patients with High-Risk Smoldering Myeloma?

Daratumumab was approved in this setting in November 2025. Does this mean we should automatically prescribe it to all high-risk patients?

Dec 1, 2025 • Timothée Olivier

7

47:51

November 2025

When the Follow-Up Ends Too Soon: Rethinking Long-Term Benefit of Immunotherapy

Over the years, our research group has written a lot on immune checkpoint inhibitors (ICIs) in cancer, in part because of the excitement over durable…

Nov 28, 2025 • Alyson Haslam

14

2

Spotting informative censoring with longer follow-ups — the NADINA and NATALEE trials show two different patterns.

My new publication, “Identifying informative censoring from censoring patterns across successive follow-ups”, is out in the European Journal of Cancer…

Nov 22, 2025 • Timothée Olivier

15

2

1

Are fears of rising cancer in young adults exaggerated? A live talk with Ade Adamson

A recent JAMA Internal Medicine study sheds light on this question!

Nov 3, 2025 • Timothée Olivier

18

3

2

38:57

October 2025

The Iceberg Plot: A Visual I Conceived to Differentiate Tumor Biology from Treatment Effect.

I would like to emphasize a plot we published together with Vinay Prasad and Mark Lythgoe.

Oct 29, 2025 • Timothée Olivier

14

2

1

Post-ESMO 2025 on Adjuvant CDK4/6 Inhibitors after MonarchE and NATALEE Updates.

With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high.

Oct 26, 2025 • Timothée Olivier

23

10

4